Oviva closes landmark €200M round to tackle obesity with AI
Berlin and Zurich-based digital health company Oviva has raised €200 million in fresh funding to expand its AI-powered obesity and metabolic care platform across more European health systems. The latest round, one of the largest in European digital therapeutics to date, underscores how payers and investors are betting on technology to address the continent’s fast-rising burden of obesity, type 2 diabetes and related chronic diseases.
Founded in 2014, Oviva partners with national health services, insurers and hospitals to deliver structured, remote-first programs for patients who are overweight or living with diet-related conditions. Its model blends certified dietitians, physicians and psychologists with AI algorithms that personalize care plans, monitor progress and flag risks in real time.
How Oviva’s AI obesity care model works
The core of Oviva’s offering is a digital care pathway that aims to replace or augment traditional in-person diet and lifestyle clinics. Patients are typically referred by their general practitioner, hospital or insurer and then onboarded into a structured program that can last from several weeks to over a year.
Hybrid human–AI care at scale
Once enrolled, patients use a mobile app to log meals, physical activity, sleep and mood, while also integrating data from wearables and connected medical devices. AI algorithms analyze these data points to:
- Identify unhealthy patterns and triggers in eating and activity
- Recommend tailored behavioral interventions
- Prioritize which patients need human outreach first
- Support clinicians with decision prompts and risk scores
Licensed dietitians and physicians then review the AI-generated insights, adjust individual care plans and provide coaching via chat, video calls and group sessions. The aim is to deliver intensive, evidence-based lifestyle interventions at a fraction of the cost of traditional clinics, while maintaining clinical quality and patient engagement.
Focus on reimbursement and clinical outcomes
Unlike many consumer wellness apps, Oviva has built its model around full or partial reimbursement by public and private payers. The company already works with major health systems in countries such as Germany, the United Kingdom, Switzerland and France, where digital therapeutics and remote patient monitoring are increasingly recognized as reimbursable services.
Peer-reviewed studies and real-world evaluations cited by Oviva show that its programs can lead to meaningful weight loss, improved blood sugar control and reduced reliance on medications for patients with type 2 diabetes and prediabetes. For payers, the promise is clear: if technology-enabled lifestyle change can prevent or delay complications such as cardiovascular disease, kidney failure and amputations, the long-term savings for public health budgets could be substantial.
Why investors are backing AI-driven obesity care
The €200 million raise comes at a time when Europe is facing what public health authorities describe as an obesity epidemic. According to the World Health Organization, more than half of adults in the European region are overweight, and nearly one in five live with obesity. The associated rise in healthcare costs, lost productivity and reduced quality of life has turned obesity into a central policy challenge for governments and insurers.
Against this backdrop, AI-powered platforms like Oviva are increasingly viewed as a way to deliver scalable, personalized interventions without overloading already stretched clinical workforces. By automating parts of data analysis, triage and patient engagement, AI algorithms can free clinicians to focus on complex cases and motivational support, rather than manual monitoring and paperwork.
Investors in the new round are betting that this combination of strong clinical need, supportive regulation for digital health, and proven reimbursement pathways will enable Oviva to become a leading European player in tech-enabled metabolic care. While the company has not publicly disclosed its valuation, the size of the round places it firmly among Europe’s most heavily funded digital health scale-ups.
Expansion strategy across European health systems
Oviva plans to use the fresh capital to deepen its presence in existing markets and enter additional European countries where obesity and metabolic disease are straining public budgets. A key part of the strategy is integrating more tightly with national electronic health record systems, referral networks and primary care providers.
Localization and regulatory alignment
Because healthcare in Europe is fragmented by country, the company must tailor its programs to different reimbursement regimes, clinical guidelines and data protection rules. That includes aligning with frameworks like Germany’s DiGA (Digital Health Applications), the UK’s NHS digital pathways, and strict GDPR requirements around patient data.
Oviva is investing in local clinical teams, language-specific content and culturally appropriate coaching models to improve engagement across diverse populations. The company also emphasizes strong data privacy and transparent consent mechanisms, as concerns over health data usage and AI ethics mount across the continent.
Integrating with new obesity drugs and treatments
The funding comes amid a surge of interest in new anti-obesity medications such as GLP-1 receptor agonists, which have shown significant weight loss effects. Rather than viewing these drugs as competition, Oviva positions its platform as a complementary tool that can help patients maintain lifestyle changes and manage side effects, potentially enhancing long-term outcomes and cost-effectiveness.
By combining pharmacological treatments with structured digital coaching and continuous monitoring, the company aims to offer health systems a more holistic approach to obesity and metabolic disease management.
Challenges and the road ahead
Despite its momentum, Oviva faces a competitive landscape that includes both traditional weight management programs and a new wave of digital therapeutics startups targeting diabetes, obesity and cardiovascular risk. Success will depend on demonstrating superior long-term outcomes, maintaining strong relationships with clinicians, and navigating tightening regulatory scrutiny of AI in healthcare.
European regulators are working on frameworks such as the EU AI Act, which will impose stricter requirements on high-risk medical AI systems. Oviva will need to ensure that its AI algorithms are transparent, auditable and free from harmful bias, particularly as it scales across different countries and demographic groups.
Still, the size of the new funding round signals confidence that technology-enabled, reimbursed obesity care is moving from niche pilot projects to mainstream healthcare infrastructure. If Oviva can translate capital into measurable public health impact, it may help redefine how European health systems approach one of their most pressing chronic disease challenges.